Immunovant
Smita Annie Maliekal is an experienced professional in the regulatory affairs sector, currently serving as the Director of Regulatory Affairs at Immunovant since December 2020, following a role as Associate Director of Regulatory Affairs Operations. Prior experience includes positions as a RIM Business Analyst at Orion Innovation for Bristol-Myers Squibb, and Sr. Manager of RIM Business Process at Amicus Therapeutics. Smita has held significant roles at Daiichi Sankyo, Bristol-Myers Squibb, and various other companies, focusing on regulatory affairs, document management systems, and technical analysis. Smita holds a Master of Science in Computer Engineering from Wright State University and a Bachelor of Engineering from Poona University.
This person is not in any teams
This person is not in any offices
Immunovant
6 followers
Immunovant, Inc. is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies.